$NPCE News

Last published 1w ago

1w agoNPCENeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026Business WireNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2026 after market close
2mo agoNPCEWells Fargo 21st Annual Healthcare Conference - NEUROPACE INCEarnings Call TranscriptsAll right. Good morning. My name is Ross Osborne. I'm on the MedTech team at Wells Fargo. This morning, we have NeuroPace. And from the company, we have the CFO, Patrick Williams, and the head of investor relations, Scot
2mo agoNPCENeuroPace to Participate in 2026 Cantor Global Healthcare ConferenceBusiness WireNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global
2mo agoNPCENeuroPace to Participate in Wells Fargo 21st Annual Healthcare ConferenceBusiness WireNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st
3mo agoNPCENeuroPace Q2 2026 Earnings Call - NEUROPACE INCEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to the NeuroPace Q2 2026 earnings call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press
3mo agoNPCENeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue GuidanceBusiness Wire--Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth-- --Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which assumes 21% to 23%
3mo agoNPCENeuroPace IGE PMA Supplement Update Call - NEUROPACE INCEarnings Call TranscriptsGreetings. Welcome to the NeuroPACE IGE PMA Supplement Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow prepared remarks. Please note this conference is bei
3mo agoNPCENeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized EpilepsyBusiness Wire-- Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form and that additional clinical evidence from the NAUTILUS trial and
5mo agoNPCENeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) MeetingBusiness Wire--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations-- --NeuroPace to engage neurosurgeon community through
5mo agoNPCENeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy CareBusiness Wire-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device
6mo agoNPCENeuroPace Q1 Earnings Call - NEUROPACE INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. My name is Abby and I will be your conference operator today. At this time, I would like to welcome everyone to the Narrow-Cased First Quarter Earnings Call. All lines hav
6mo agoNPCENeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue GuidanceBusiness Wire--Total revenue of $22.1 million-- -- Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 million previously-- --Assumes 21% to 23% growth in core RNS® revenue from
6mo agoNPCENeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026Business WireNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2026 after market close
6mo agoNPCENeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026Business Wire— Published 3-year Post-Approval Study results show 82% median seizure reduction in drug-resistant focal epilepsy — — American Academy of Neurology (AAN) presentation featured 12- and 18-month NAUTILUS data, the first
7mo agoNPCENeuroPace to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness WireNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual Needham Virtual
8mo agoNPCELEERINK GLOBAL HEALTHCARE CONFERENCE - NEUROPACE INCEarnings Call TranscriptsOkay, we can kick things off. Thanks, everybody, for joining. I'm Mike Racky. I am our senior MedTech analyst here at Lear Inc. and very pleased to be joined today by NeuroPace CEO Joel Becker and CFO Patrick Williams. A
8mo agoNPCENeuroPace to Present at the Leerink Global Healthcare ConferenceBusiness WireNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026 Global Healthcare
8mo agoNPCENeuroPace Q4 Earnings Call - NEUROPACE INCEarnings Call TranscriptsGood afternoon, and welcome to NeuroPace's fourth quarter 2025 conference call. As a reminder, this call is being recorded. I would now like to turn the call over to Scott Schaefer, Head of Investor Relations at Neuro Pa
8mo agoNPCENeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 OutlookBusiness Wire-- Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth -- -- Reiterates previously issued 2026 guidance assuming 20% to 22% growth in core RNS® revenue from existing indications,
8mo agoNPCENeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026Business WireNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market
10mo agoNPCENeuroPace to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual J.P. Morgan Healthcare
10mo agoNPCENeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized EpilepsyBusiness Wire-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures -- NeuroPace, Inc. (NASDAQ:NPCE),
11mo agoNPCENeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized EpilepsyBusiness Wire-- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) -- -- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting
11mo agoNPCENeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual MeetingBusiness Wire--Data presentations to feature 18-month NAUTILUS results and new Post Approval Study (PAS) analyses on GTC seizure reduction-- --RNS® System to be featured in over 80 scientific presentations and posters, the
11mo agoNPCENeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient ServicesBusiness Wire--Physician Fee Schedule (PFS) final rule substantially increases reimbursement for RNS neurostimulator implantation and replacement procedures-- --CY 2026 Outpatient Prospective Payment System (OPPS) Final Rule moves
1y agoNPCENeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue GuidanceBusiness Wire-- Reported record quarterly revenue of $27.4 million in Q3 2025 representing 30% growth -- -- Increased full-year 2025 revenue guidance to between $97 million and $98 million and gross margin guidance to between 76%
1y agoNPCENeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025Business WireNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2025 after market close
1y agoNPCENeuroPace to Participate in Upcoming Healthcare ConferencesBusiness WireNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in two healthcare conferences in
1y agoNPCENeuroPace, Inc. (NPCE) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoNPCENeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue GuidanceGlobeNewswire-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on
1y agoNPCENeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator CasesGlobeNewswireMOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following
1y agoNPCENeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025GlobeNewswireMOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report
1y agoNPCENeuroPace Announces Strategic CFO TransitionGlobeNewswireAppoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW,
1y agoNPCENeuroPace Secures Up to $75 Million in Debt FinancingGlobeNewswireMOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has
1y agoNPCENeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS StudyGlobeNewswire-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week
1y agoNPCENeuroPace Reports First Quarter 2025 Financial ResultsGlobeNewswire-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to
1y agoNPCENeuroPace Provides Update on Tariff StatusGlobeNewswire-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc.
1y agoNPCENeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual MeetingGlobeNewswireThree-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1Long-term seizure reduction with a median reduction of 82% at 3 years.Seizure
1y agoNPCENeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual MeetingGlobeNewswireMOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at
1y agoNPCENeuroPace Announces Refocusing of Product PortfolioGlobeNewswire-- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 -- -- Maintaining 2025 Revenue Guidance -- -- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and
1y agoNPCENeuroPace to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireMOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management
1y agoNPCENeuroPace Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net
1y agoNPCEUPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare ConferenceGlobeNewswireMOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management
1y agoNPCENeuroPace to Present at the Leerink Partners Global Healthcare ConferenceGlobeNewswireMOUNTAIN VIEW, Calif. , March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management
1y agoNPCENeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.GlobeNewswireMOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it has completed the
1y agoNPCENeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025GlobeNewswireMOUNTAIN VIEW, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report
1y agoNPCENeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional SharesGlobeNewswireMOUNTAIN VIEW, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE) today announced the completion of its previously announced underwritten public offering of 7,475,000 shares of its common stock at
1y agoNPCENeuroPace Announces Pricing of Public Offering of $65 Million of Common StockGlobeNewswireMOUNTAIN VIEW, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price
1y agoNPCENeuroPace Announces Proposed Public Offering of $65 Million of Common StockGlobeNewswireMOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of its common stock.
1y agoNPCENeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9thGlobeNewswireMOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that an abstract